Form 4: Pharvaris CTO Stefan Abele Sells 8,748 Shares

Chief Technical Operations Officer Stefan Abele sold 8,748 shares of Pharvaris N.V. common stock at an average price of $29.8199.

Summary

• Stefan Abele, Chief Technical Operations Officer of Pharvaris N.V., executed a sale of 8,748 shares of common stock.
• The transaction occurred on May 15, 2026, at a price of $29.8199 per share.
• Following this transaction, the reporting person retains beneficial ownership of 35,194 shares of common stock.
• The shares sold include common stock acquired upon the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction appears to be a routine divestment of vested equity rather than a signal of fundamental change in company outlook.

Positives

• The reporting person maintains a significant remaining stake of 35,194 shares in the company.

Negatives

• The transaction represents a divestment of equity by a key member of the executive management team.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or future financial performance.

Industry Context

StockSavvy.ai notes that executive stock sales are common in the biotechnology sector, often occurring to cover tax obligations related to the vesting of equity-based compensation or as part of pre-planned financial diversification strategies.

Comparison to Industry Standards

• The sale of shares by an executive following the vesting of restricted stock units is a standard practice in the pharmaceutical and biotech industries.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, which is typical for routine executive transactions.

Stakeholder Impact

• Minimal impact expected on shareholders as this is a standard executive transaction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Biotech, Executive Stock Sale